Zymeworks Inc Stock News

VANCOUVER, British Columbia & SEATTLE--(BUSINESS WIRE)--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that management will participate in upcoming investor conferences. Guggenheim Oncology Conference 2022. Zymeworks will participate virtually in one-on-one meetings and a fireside chat on February 9th at 1:00 p.m. ET. 11th Annual SVB Leerink Global Healthcare Conference. Zymeworks will participate virtually in

VANCOUVER, British Columbia & SEATTLE--(BUSINESS WIRE)--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that managem

Zymeworks Inc. (ZYME) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more stre

Zymeworks Inc. (ZYME) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more stre

Zymeworks Inc. (ZYME) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings esti

Zymeworks Inc. (ZYME) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings esti

Want to try a different approach? Tap five stocks with increasing P/E ratios such as MEDIFAST (MED), JAKKS Pacific (JAKK), Asbury Automotive Group (ABG), Zymeworks (ZYME) and Polaris (PII).

Want to try a different approach? Tap five stocks with increasing P/E ratios such as MEDIFAST (MED), JAKKS Pacific (JAKK), Asbury Automotive Group (ABG), Zymeworks (ZYME) and Polaris (PII).

Zymeworks is looking to raise $100 million in a public offering, barely a week since new CEO Kenneth Galbraith took the reins of the biotech company, which has operations in Seattle and Vancouver, B.

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Atara To Sell Manufacturing Plant to Fuji's CDMO Unit For $100M Atara Biotherapeutics, Inc. (NASDAQ: A

Zymeworks <> shares have set a new 52-week low after the company announced a 25% reduction in its employee headcount by the end of the year

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Eisai Announces Publication Of Positive Data On Lenvima-Keytruda Combo In Endometrial Cancer Eisai Co.

Zymeworks Inc (NYSE: ZYME ) said that in conjunction with the renewed focus on key priorities and cost-efficiency, ten members (or 50%) of the former senior management team would be leaving the Company. Additionally, in line with these reductions in the senior management team, a Company-wide decrease in the workforce will be initiated with a target of reducing Full story available on Benzinga.com

Zymeworks (ZYME) confirms 2022 and 2023 clinical development milestones for zanidatamab and ZW49.In addition, ten members (or 50%) of the former senior management team (including the

RentACenter, U.S. Physical Therapy, Cellectar Biosciences, Toro and Zymeworks are highlighted in this Screen of the Week article.